Sarepta Therapeutics Inc (SRPT)
114.23
+3.73
(+3.38%)
USD |
NASDAQ |
Nov 22, 16:00
114.23
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Free Cash Flow: -480.40M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -480.40M |
| June 30, 2024 | -527.92M |
| March 31, 2024 | -653.88M |
| December 31, 2023 | -588.34M |
| September 30, 2023 | -615.20M |
| June 30, 2023 | -534.14M |
| March 31, 2023 | -469.85M |
| December 31, 2022 | -357.60M |
| September 30, 2022 | -290.88M |
| June 30, 2022 | -350.03M |
| March 31, 2022 | -389.18M |
| December 31, 2021 | -483.97M |
| September 30, 2021 | -653.28M |
| June 30, 2021 | -783.19M |
| March 31, 2021 | -794.93M |
| December 31, 2020 | 25.26M |
| September 30, 2020 | 47.36M |
| June 30, 2020 | 233.99M |
| March 31, 2020 | 265.07M |
| December 31, 2019 | -516.09M |
| September 30, 2019 | -475.03M |
| June 30, 2019 | -532.66M |
| March 31, 2019 | -563.81M |
| December 31, 2018 | -449.82M |
| September 30, 2018 | -345.41M |
| Date | Value |
|---|---|
| June 30, 2018 | -276.58M |
| March 31, 2018 | -238.12M |
| December 31, 2017 | -253.21M |
| September 30, 2017 | -302.21M |
| June 30, 2017 | -298.33M |
| March 31, 2017 | -254.02M |
| December 31, 2016 | -252.69M |
| September 30, 2016 | -200.91M |
| June 30, 2016 | -186.94M |
| March 31, 2016 | -172.29M |
| December 31, 2015 | -154.30M |
| September 30, 2015 | -150.40M |
| June 30, 2015 | -150.81M |
| March 31, 2015 | -165.75M |
| December 31, 2014 | -155.36M |
| September 30, 2014 | -145.01M |
| June 30, 2014 | -118.35M |
| March 31, 2014 | -86.89M |
| December 31, 2013 | -68.47M |
| September 30, 2013 | -57.50M |
| June 30, 2013 | -43.83M |
| March 31, 2013 | -36.99M |
| December 31, 2012 | -30.84M |
| September 30, 2012 | -29.69M |
| June 30, 2012 | -29.65M |
Free Cash Flow Range, Past 5 Years
-794.93M
Minimum
Mar 2021
265.07M
Maximum
Mar 2020
-395.86M
Average
-482.19M
Median
Free Cash Flow Benchmarks
| Eli Lilly and Co | -2.275B |
| Catalyst Pharmaceuticals Inc | 221.79M |
| Regeneron Pharmaceuticals Inc | 3.319B |
| Vertex Pharmaceuticals Inc | -1.352B |
| Viking Therapeutics Inc | -74.25M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -70.70M |
| Cash from Investing (Quarterly) | -128.82M |
| Cash from Financing (Quarterly) | 13.76M |
| Free Cash Flow Per Share (Quarterly) | -1.075 |
| Free Cash Flow to Equity (Quarterly) | -109.21M |
| Free Cash Flow to Firm (Quarterly) | -107.96M |
| Free Cash Flow Yield | -4.18% |